PART B - FEE(S) TRANSMITTAL

Completé and send this form, together with applicable fee(s), to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450

Alexandria, Virginia 22313-1450

or <u>Fax</u> (571) 273-2885



appropriate All further cor	respondence including the below or directed otherwise	Patent advance or	ders and noti	PUBLICATION FEE (if requirements of maintenance fees in new correspondence address	will be mailed to the current	correspondence address as
CURRENT CORRESPONDENCE	E ADDRESS (Note: Use Block 1 for	any change of address)		Note: A certificate of	mailing can only be used for its certificate cannot be used	or domestic mailings of the
96056	7590	96 F1201P		papers. Each addition	al paper, such as an assignment of mailing or transmission.	ent or formal drawing, must
Florek & Endres PLLC 1156 Avenue of the Ar Suite 600 NEW YORK, NY 1003	mericas	JUL 192	010 B	Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (371) 273-2885, on the date indicated below.		
		THE WAR	ART	Martin P. Endres		(Depositor's name)
		TRADE	Mi	9 Mil) -	(Signature)
				July 14, 2010		(Date)
APPLICATION NO.	FILING DATE	FIRST NAMED		INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/664,803	09/19/2003		Unchalee I	Kositprapa	141-424	3478
TITLE OF INVENTION:						
NOVEL PHARMACEUT	TICAL FORMULATION CO	ONTAINING A BIO	GUANIDE A	ND A THIAZOLIDINEDION	E DERIVATIVE	
APPLN. TYPE	SMALL ENTITY	ISSUE FEE		PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510		\$300	\$1810	09/24/2010
EXAMINER		ART UNIT		CLASS-SUBCLASS		
SASAN, ARADHANA		1615		424-484000	_	
☐ "Fee Address" indicate	e address or indication of "F dence address (or Change of 22) attached. tion (or "Fee Address" Indic. or more recent) attached. Use	Correspondence	2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.			
3. ASSIGNEE NAME AND						
PLEASE NOTE: Unless recordation as set forth in	an assignee is identified by 37 CFR 3.11. Completion	clow, no assignee of this form is NOT	data will app Fa substitute	car on the patent. If អ្នក (នង់ដែ for filing an assignment	<u> 1904 us 1904 ament 6800 ament</u> 1904 us	1510.00 OP
						300.00 OP
Watson Pharmaceuticals, Inc. Corona, Claifornia 92880						
Please check the appropriate	assignee category or catego	ories (will not be pri	inted on the p	atent): 🔲 Individual 🖾 C	Corporation or other private gr	oup entity Government
4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):						
☑ Issue Fee ☑ A check in the amount of the fec(s) is enclosed.						
□ Publication Fee (No small entity discount permitted) □ Payment by credit card. Form PTO-2038 is attached. □ Advance Order - # of Copies □ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to						
Advance Order - # 01	Copies		Deposit Acc	ount Number 50-522	(enclose an extra c	opy of this form).
5. Change in Entity Status a. Applicant claims S	(from status indicated above MALL ENTITY status. Sec	•	b. Applic	ant is no longer claiming SMA	ALL ENTITY status. See 37 C	FR 1.27(g)(2).
The Director of the USPTO NOTE: The Issue Fee and P interest as shown by the reco	is requested to apply the Iss ublication Fee (if required) ords of the United States Pat	ue Fee and Publicat will not be accepted ent and Trademark	ion Fee (if an I from anyone Office.	y) or to re-apply any previous to other than the applicant; a reg	ly paid issue fee to the applica pistered attorney or agent; or t	tion identified above. he assignee or other party in
Authorized Signature	MONDO	<u></u>		Date	July 14, 201	0
Typed or printed name Martin P. Endres					n No. <u>35,498</u>	
This collection of informatic an application. Confidential	on is required by 37 CFR 1.3 ity is governed by 35 U.S.C	11. The informatio	n is required 1 1.14. This col	to obtain or retain a benefit by lection is estimated to take 12	the public which is to file (an minutes to complete, including	d by the USPTO to process) ng gathering, preparing, and

submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450

or Fax (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 06/24/2010 96056 7590 Florek & Endres PLLC Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. 1156 Avenue of the Americas Suite 600 NEW YORK, NY 10036 JUL 1 9 2010 -Endres (Depositor's name) (Signature) (Date) July 14, 2010 FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE 09/19/2003 Unchalee Kositprapa 141-424 3478 10/664.803 TITLE OF INVENTION: NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE DATE DUE SMALL ENTITY **ISSUE FEE PUBLICATION FEE** TOTAL FEE(S) DUE APPLN, TYPE 09/24/2010 \$1810 NO \$1510 \$300 nonprovisional ART UNIT CLASS-SUBCLASS **EXAMINER** 424-484000 SASAN, ARADHANA 1615 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list I Florek & Endres PLLC (1) the names of up to 3 registered patent attorneys Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) (A) NAME OF ASSIGNEE Corona, Claifornia 92880 Watson Pharmaceuticals, Inc. Please check the appropriate assignee category or categories (will not be printed on the patent): 🔲 Individual 🖾 Corporation or other private group entity 🚨 Government 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): ☑ Issue Fee A check in the amount of the fee(s) is enclosed. ☐ Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Order - # of Copies The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 50-5222 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

14,2010 Authorized Signature Date Typed or printed name Martin P. Endres Registration No. 35,498

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.